A5039344496- Sarcoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Cutaneous Melanoma Detection and Management
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Melanoma and MAPK Pathways
- Oral and Maxillofacial Pathology
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Brain Metastases and Treatment
- CAR-T cell therapy research
- Ultrasound and Hyperthermia Applications
- Musculoskeletal synovial abnormalities and treatments
- Reconstructive Surgery and Microvascular Techniques
- Cutaneous lymphoproliferative disorders research
- Lung Cancer Research Studies
- Ear and Head Tumors
- Marketing and Advertising Strategies
- Cardiac Health and Mental Health
- Inflammatory Myopathies and Dermatomyositis
- 3D Printing in Biomedical Research
- Lung Cancer Diagnosis and Treatment
- Infectious Diseases and Mycology
The Maria Sklodowska-Curie National Research Institute of Oncology
2016-2025
National Institute of Geriatrics, Rheumatology and Rehabilitation
2024
Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive that rarely metastasizes and typically occurs in the bones. At present, primary treatment for GCTB curettage with local adjuvants. cells express receptor activator nuclear factor-κB ligand (RANKL). Denosumab, a RANKL inhibitor appears to present effective therapeutic option advanced cases GCTB. The aim study was confirm efficacy denosumab large group patients A total 35 histologically confirmed were treated no participation...
Introduction: Myxoid liposarcoma (MLPS) has been reported to be more radiosensitive compared with other soft tissue sarcomas. The main objective of the study was assess efficacy hypofractionated radiotherapy (RT) in preoperative setting patients locally advanced primary MLPS. Methods: Single-arm prospective exploratory clinical trial enrolled MLPS for 5 × Gy RT delayed surgery. endpoints were rate early wound healing complications and 5-year local control rate. Results: 29 (pts) included,...
Background: The use of adjuvant radiotherapy (RT) shows a significantly decreased incidence local recurrence (LR) in soft tissue sarcomas (STS). This study aimed to assess the treatment scheme’s effect patients with primary STS treated at one institution. Methods: In this phase 2 trial, 311 aged ≥18 years primary, locally advanced extremity or trunk wall were assigned multimodal therapy conducted preoperative RT scheme consisted 5 Gy per fraction for total dose 25 Gy. Surgery was performed...
Background: The evidence base for the management of oligoprogression in metastatic melanoma (MM) is limited. To our knowledge, this study presents first analysis local benefit (LB) radiotherapy combined with hyperthermia during systemic treatment diagnosis. Methods: Patients oligoprogressive MM who were treated (RTH) (HT) at a center between 2019 and 2023 evaluated. Oligoprogression was defined as up to five progressive metastases. Inclusion criteria availability dimensions assessment lesion...
Background Chordoma is a rare and aggressive primary bone sarcoma. En-block resection remains the treatment, but some patients are unable to undergo it due location potential complications. Currently, there no direct comparison of effects radiotherapy (RTH) surgical treatment. However, retrospective analyses indicate benefits using RTH. Methods A analysis was conducted on 48 with sacral chordoma who were treated surgery and/or between 2001-2020. Among those, 22 initially surgery, 19...
Introduction: Management of marginally resectable or unresectable soft tissue sarcomas (STS) in patients who are not candidates for neoadjuvant chemotherapy due to chemoresistant pathology contraindications remains a challenge. Therefore, these indications, we aimed investigate feasibility 10x 3.25 Gy radiotherapy combined with regional hyperthermia (HT) that could be followed by surgery 4x 4 HT. Materials and methods: We recruited locally advanced STS (1) presented subtype, (2) progressed...
Abstract Background Neoadjuvant–adjuvant therapy for locally advanced or potentially resectable metastatic melanoma was expected to improve operability and clinical outcomes over upfront surgery adjuvant treatment only. Methods Forty‐seven consecutive patients were treated with neoadjuvant–adjuvant BRAF inhibitors (BRAFi)/MEK (MEKi) surgery. Results Twelve (26%) achieved a pathological complete response 10 (21%) near‐complete response. In the whole group, median recurrence‐free survival 19.4...
// Aneta Borkowska 1 , Anna Szumera-Ciećkiewicz 2 3 Mateusz Spałek Paweł Teterycz Czarnecka 4 Artur Kowalik 5 6 and Piotr Rutkowski Department of Soft Tissue/Bone Sarcoma Melanoma, Maria Sklodowska-Curie National Research Institute Oncology, Warsaw, Poland Pathology Laboratory Medicine, Diagnostic Hematology Department, Transfusion Experimental Pharmacology, Mossakowski Medical Centre, Polish Academy Sciences, Molecular Diagnostics, Holy Cross Cancer Kielce, Division Biology, Jan Kochanowski...
The landscape of melanoma management changed as randomized trials have launched adjuvant treatment.An analysis data on 248 consecutive stage III and IV patients given therapy in eight centers (February 2019 to January 2021) was conducted.The analyzed cohort comprised 147 anti-PD1 (33% nivolumab, 26% pembrolizumab), 101 (41%) were dabrafenib plus trametinib (DT). 2-year overall survival (OS), relapse-free (RFS), distant-metastases-free (DMFS) rates 86.7%, 61.4%, 70.2%, respectively. disease...
Selected patients with locally advanced or metastatic soft tissue and bone sarcomas (STBS) may benefit from intensive local treatment, such as stereotactic radiotherapy (SRT). This study aimed to summarize the utilization outcomes of SRT in STBS identify predictive factors for progression survival.Consecutive who underwent a sarcoma tertiary center were identified. We collected tumor- treatment-related factors. Endpoints comprised time (TTLP), progression-free survival (LPFS), progression,...
Cutaneous melanomas located on the acral part of extremities (hand and foot melanoma; HFM) comprise a rare group within all in Caucasians. HFM is associated with poor prognosis. We aimed to evaluate clinicopathological features, long-term outcomes, prognostic factors primary Caucasians.Medical records consecutive patients treated between 1997 2014 were revised. Patients diagnosed cutaneous melanoma at I-II clinical stage, sentinel lymph node biopsy was conducted. The analysis performed...
Neoadjuvant therapy for locally advanced disease or potentially resectable metastatic melanoma is expected to improve operability and clinical outcomes over upfront surgery adjuvant treatment as it sarcoma, breast, rectal, esophageal, gastric cancers. Patients with locoregional recurrence after initial those regional lymphatic metastases are at a high risk of relapse melanoma-related death. There an unmet need the such patients. bulky stage III IV histologically confirmed were enrolled...